

**Efficacy of Skin Microneedling in combination with Narrow-Band Ultraviolet B Phototherapy in Vitiligo**

**Abstract**

**Background:** Vitiligo is a chronic cutaneous disease characterized by milky white depigmented patches that leave psychological impact on the patient's quality of life. New treatment modalities have been developed to shorten the duration of treatment of vitiligo with the least side effects.

**Objective:** To evaluate the safety & efficacy of microneedling in combination with NB-UVB in the treatment of vitiligo.

**Patients and methods:** This study included 20 patients with stable vitiligo. They were treated by microneedling (one session every 2 weeks) in combination with NB-UVB (3 sessions weekly) for 3 months.

**Results:** The studied patients reported statistically significant degree of clinical improvements as follow; 10% reported good improvement, 25% showed moderate improvement, 45% showed mild improvement and 20% showed no improvement, after 3 months therapy. The reported side effects were minimal and transient in the form of minor pain, burning sensation and erythema at site of microneedling that disappeared spontaneously within few hours.

**Conclusion:** Microneedling in combination with NB-UVB phototherapy could be considered as effective treatment of vitiligo. Microneedling is a tolerable technique, harmless with negligible side effects.

**Keywords:** Microneedling; NB-UVB; Vitiligo.

UNDER PEER REVIEW

## **Introduction**

Vitiligo is an acquired cutaneous achromia characterized by milky white cutaneous patches of various sizes and shapes resulting from loss of epidermal melanocytes. Multiple mechanisms have been suggested to be involved in loss of melanocyte: genetic predisposition, environmental triggers, metabolic abnormalities, altered inflammatory and immune responses, the autoimmune theory is the leading hypothesis<sup>(1)</sup>. The prevalence of the disease varies between 0.1- 4% of the world population of all skin types, races, and both sexes. There are several treatment modalities for vitiligo, such as topical corticosteroid, vitamin D3 analogue derivatives, calcineurn inhibitors, photochemotherapy and eximer laser<sup>(2)</sup>.

Microneedling is a relatively slightly invasive technique involving superficial and controlled puncturing of the skin by rolling with miniature fine needles<sup>(3)</sup>. It improves drug penetration through stratum corneum, which might potentiate their activity<sup>(4)</sup>. In addition, it induces processes similar to wound healing with production of cytokines and growth factor beneficial for repigmentation. Needling is used for treating localized vitiligo alone or in combination with NB-UVB with quite satisfying therapeutic results<sup>(5)</sup>.

The aim of our work is to evaluate the safety & efficacy of microneedling in combination with NB-UVB in the treatment of vitiligo.

## **Patients and Methods:**

This study included 20 patients; they were collected from the Outpatient Clinic of Dermatology and Venereology Department, Tanta University Hospitals, Egypt, during the period from Jan 2018 to Jan 2019.

## **Inclusion Criteria:**

1. Patients with stable vitiligo for at least 1 year.
2. Patients with vitiligo who stopped receiving any treatment (systemic, topical, or phototherapy) for the last 3 months.
3. Patients with no other dermatological or systemic diseases.

**Exclusion criteria:**

1. Patients with active vitiligo.
2. Patients who have any other dermatological diseases.
3. Patients suffering from acute and chronic diseases such as (kidney and liver disease, ischemic heart disease or oncological diseases).
4. Bleeding and coagulation disorders and anticoagulant users.
5. Pregnancy and lactation.

**Treatment Procedure:**

Each patient treated as follow; microneedling (one session every 2 weeks) in combination with NB-UVB (3 sessions weekly), for 3 months. Patients were photographed at the first visit and at the end of therapy.

**NB-UVB therapy:**

All patients received NB-UVB sessions 3 times per week for 3 months. The NB-UVB source was eight NB fluorescent tubes (Philips TL 100, Hamburg, Germany) with a spectrum of 310–315 nm and a maximum wave length of 311 nm installed in a Waldmann UV-100 unit. The dose of UVB was 0.33 J/cm<sup>2</sup> (we started with 0.21 J/cm<sup>2</sup> and increased gradually by 20% every session till the minimal erythema dose was achieved).

**Microneedling method:**

The microneedling session was done using Dermapen (MY M microneedling, korea) Adaptor was plugged into the hand piece. Sterilized needle was put into the top of the hand piece. The depth of needle was set at (needle depth 01.0 to 2.0 mm) by turning the adjustment ring. Dermapen then was applied perpendicular on the treated area moving vertically and horizontally. The end point was the development of erythema.

### **Evaluation of the treatment**

The patients were examined in the first visit and were reviewed weekly for the progress of therapy and the presence of any side effects. The repigmentation response was expressed qualitatively as: No change (0%), mild (1 –25%), moderate (26–50%), good (51 –75%), excellent (76 –99%), complete regimentation (100%)<sup>(5)</sup>.

### **Patient's satisfaction**

It is the degree of improvement according to the patient opinion. The patients were asked at the final visit about the overall satisfaction according to whether the patient not satisfied, satisfied or very satisfied.

### **Safety assessment**

The patients were informed to report any complications as; burning sensation, inflammation, infection, ecchymosis, or any allergic manifestations.

### **Follow-up assessment**

The patients were followed-up monthly for 3 months after the end of the treatment sessions to detect any recurrence, complications or worsening of the lesions.

### **Statistical analysis**

The data were collected, tabulated and statistically analyzed using SPSS software statistical computer package version 12. For quantitative data, the mean and standard deviation were calculated. The difference between two means was statistically analyzed using the Student's t-test. P-value less than 0.05 was considered statistically significant.

## **Results**

This study included 20 vitiligo patients. Regarding the gender of the patients; there were 8 males (40%) and 12 females (60%). The age of the patients ranged from 10 to 52 years. Two patients (10%) had positive family history of vitiligo while 18 patients (90%) had negative family history of the disease. Regarding the skin type of the patients, 15 patients (75%) were skin type III and 5 patients (25%) were of skin type IV. While regarding the duration of vitiligo; it ranged from 2.6 to 12 years (Table 1).

## **Clinical assessment**

The present study didn't report excellent improvement in any patient, only two patients (10%) reported good improvement, 5 patients (25%) showed moderate improvement, 9 patients (45%) showed mild improvement and 4 patients (20%) showed no improvement, (Table 2).

Regarding patients satisfaction, 3 patients (15%) were very satisfied, 8 patients (40%) were satisfied, and 9 patients (45%) showed not satisfied, (Table 3).

Regarding the side effects, all patients tolerated the treatment well. The adverse reactions were minimal and transient in the form of burning sensation, inflammation at site of microneedling that disappeared spontaneously within few hours. However, recurrence reported in 3 patients (15%) after 3 month from last session.

## **Discussion**

The aim of treatment in vitiligo is to restore the normal appearance, morphology, and function of the skin. Several treatment modalities are currently available for treatment of vitiligo that can be broadly classified under medical and surgical modalities; each having certain indications and limitations. A combination of traditional and newer treatments may work synergistically to provide additional improvement in patients' disease state, quality of life and reduce the potential side effects <sup>(1,2)</sup>. In this work we tried to evaluate the efficacy and safety of microneedling in association with NB-UVB in the treatment of vitiligo.

At the end of follow up period (3 months after last session), different grades of repigmentation were observed in 80% of patients with good improvement in 10%, moderate improvement in 25%, and mild improvement in 45%.

The results of Batool et al., <sup>(6)</sup> were superior to our result. They reported that patients with vitiliginous patches who were treated (three/week) by needling with insulin syringe, and then were given narrowband UVB sessions for at least six months, showed very good to excellent improvement in about 91% of patches.

Mohaghegh et al., <sup>(7)</sup> tried to assess the efficacy of NB-UVB therapy with and without needling in treatment of vitiligo. The patches included in their study were divided into A and B groups. Both groups received NB-UVB (three/week) for three months. In addition, the B side also received needling by insulin syringe. Side B had statistically greater improvement in pigmentation with 41.5% achieving very good level of repigmentation.

Ahmad et al., <sup>(5)</sup> also mentioned that, needling is a safe, effective and promising adjuvant treatment to NB-UVB for repigmentation of non- responding localized vitiligo, as 90% of treated patches showed good to excellent response after six months of needling with NB-UVB exposures without evident side effects.

Attwa et al., 2019<sup>(8)</sup> in a study to assess the effectiveness of using microneedling prior to application of topical 5-FU in treatment of localized vitiligo and to compare its results with microneedling alone, microneedling performed with dermapen (Dr Pen Derma Pen Ultima M5®) with needle length (1- 2 mm according to the treated site). In patch A treated by microneedling alone, there was no excellent or very good grades of repigmentation, while one patient (3.7%) showed good grade, 4 patients (14.8%) showed satisfactory grade, and 22 patients (81.5%) showed poor grade of repigmentation. In addition, Sheikh<sup>(9)</sup> conducted a study to evaluate the efficacy of combination of needling and NB-UVB for treatment of vitiligo. They reported that this combination regimen is very safe and effective against vitiligo as compared to UVB alone in all age groups.

In contrast to our result, Ebadi et al.,<sup>(10)</sup> who used needling once per week and UVB 3 times per week and the overall repigmentation was low about (15.57%). Therefore, they suggested that needling is not recommended.

One of the remarkable finding in our study was that, the reported side effects of microneedling were few and minor, and all patients tolerated the procedure well. Pain occurred in all cases during microneedling session, and reduced when local anesthesia was applied. Erythema occurred in all cases and also disappeared within 24 hours. This may indicate that microneedling could be considered safe and tolerable technique for treatment of vitiligo, consistent with our results, previous studies done by Ahmad et al.,<sup>(5)</sup>.

Microneedling instruments are devices of rows of fine needles, which are stamped over the skin to create rapidly healing punctures, resulting in a wound-healing response and subsequent collagen and elastin production. This technique is also used to augment transdermal drug delivery through pores created through the stratum corneum<sup>(11)</sup>. It is an evolving treatment modality for a growing number of dermatologic conditions<sup>(12)</sup>.



To understand the mechanism by which microneedles increase skin permeability and enhance drug delivery through the skin by increasing skin blood perfusion, A Laser Doppler Perfusion Monitor was used to record maximum blood flow and the time needed to reach maximum blood flow in the treatment areas. Sections treated with microneedles showed a higher maximum blood flow and reached maximum blood flow faster than sites not treated with microneedles <sup>(13)</sup>.

Microneedling expand the scope of transdermal delivery by creating microscopic channels that enhance the delivery of therapeutic agents ranging in size from small molecules (including drug-loaded nanoparticles) to macromolecules such as proteins across the skin <sup>(14)</sup>.

Small and very sharp microneedles have sufficient length and strength to penetrate the stratum corneum and epidermis but do not stimulate the nerve fibers and blood vessels <sup>(15)</sup>. These microchannels are reversible in nature and close within a few hours of microporation; the time frame being dependent on the length of the microneedles. This reversible nature of microchannels is very advantageous for the controlled delivery of cosmetic agents/therapeutic compounds <sup>(16)</sup>.

Microneedling does not target specific chromophores in the skin or use thermal energy, and therefore has minimal effect on pigmentation <sup>(17)</sup>. It is also suggested that repigmentation of white patches with needling occurs mainly from melanocytes which are physically dragged or pushed by the tip of the needle from colored margins of the patch or islands of pigment present within the patch. These islands are either already present or are produced during needling and serve as a source of melanocytes available for further spread <sup>(9)</sup>.

## **Conclusion**

In conclusion, skin microneedling combined with NB-UVB is safe and effective in the treatment of stable vitiligo. Further studies with larger number of cases, longer treatment periods, and follow up could be helpful to determine whether increasing the duration of therapy may result in better response and to determine the stability of repigmentation and long term safety of the treatment.

### References:

1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. *J Am Acad Dermatol* 2011;65(3):473-491.
2. Faria AR, Tarlé RG, Dellatorre G, Mira MT, Castro CC. Vitiligo--Part 2--classification, histopathology and treatment. *An Bras Dermatol* 2014;89(5):784-790.
3. El-Domyati M, Barakat M, Awad S, Medhat W, El-Fakahany H, Farag H. Microneedling therapy for atrophic acne scars: an objective evaluation. *J Clin Aesthet Dermatol* 2015; 8(7); 36–42.
4. Kim K S, Ita K, Simon L. Modelling of dissolving microneedles for transdermal drug delivery: theoretical and experimental aspects. *Eur J Pharma Sci* 2015; 68; 137–43.
5. Ahmad TJ, Rashid T, Rani Z. Needling: an adjunct to narrowband ultraviolet B therapy in localized fixed vitiligo. *J Pak Assoc Dermatol* 2016; 18(3); 149–53.
6. Batool S, Malik L, Jahangir M. Efficacy of narrowband ultraviolet B phototherapy with needling in patients of vitiligo. *J Pak Ass Dermatol* 2015; 25 (3); 177–82.
7. Mohaghegh F, Asilian A, Faghihi G, Adibi N. A comparison between the efficacy of narrow band ultra violet B phototherapy with and without needling of the lesion in the

- treatment of vitiligo. *J Res Med Sci* 2012; 17: 131–3.
8. Attwa EM, Khashaba SA, Ezzat NA. Evaluation of the additional effect of topical 5-fluorouracil to needling in the treatment of localized vitiligo. *J Cosmet Dermatol* 2019.
  9. Sheikh MI. Needle sheikhing treatment of vitiligo, a study of needling+ UVB for vitiligo. *Cosmetol J* 2017: 1(1); 101.
  10. Ebadi A, Moravvej H, Hejazi S, Younespour S, Ghalamkarpour F. Efficacy and tolerability of needling as an adjuvant to narrowband ultraviolet B therapy in the treatment of vitiligo: a clinical trial. *Iran J Dermatol* 2013; 16; 89–93.
  11. Arora S, Bhandaree PG. Automated microneedling device – a new tool in dermatologist’s kit – a review. *J Pak Assoc Dermatol* 2012; 22(4); 354–7.
  12. Nair PA, Arora TH. Microneedling using dermaroller: a means of collagen induction therapy. *GMJ* 2014; 69; 24–7.
  13. Banks S, Pinninti R , Gill G, Crooks P, Prausnitz M, Stinchcomb A. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. *Pharm Res* 2008; 25(7); 1677–85.
  14. Li G, Badkar A, Kalluri H, Banga AK. Microchannels created by sugar and metal microneedles: characterization by microscopy, macromolecular flux and other techniques. *J Pharm Sci* 2010; 99(4):1931–41.
  15. Andrews SN, Jeong E, Prausnitz MR. Transdermal delivery of molecules is limited by full epidermis, not just stratum corneum. *Pharm Res* 2013; 30(4); 1099–109.
  16. Kalluri H, Kolli CS, Banga AK. Characterization of microchannels created by metal microneedles: formation and closure. *AAPS J* 2011; 13(3); 473–81.

17. Seo K, Kim D, Lee S, Yoon M, Lee H. Skin rejuvenation by microneedle fractional radiofrequency and a human stem cell conditioned medium in Asian skin: a randomized controlled investigator blinded split-face study. *J Cosmet Laser Ther* 2013; 15(1); 25–33.

**Tables:**

**Table (1):** Distribution of the studied cases according to different parameters (n= 20)

	<b>No. (%)</b>
<b>Age</b>	
≤20	10 (50%)
>20	10 (50%)
<b>Sex</b>	
Male	8 (40%)
Female	12 (60%)
<b>Type of vitiligo</b>	
Ns localized	9 (45%)
Ns generalized	11 (55%)
<b>Duration of disease by years</b>	
≤5	14 (70%)
>5	6 (30%)
<b>Site of lesion</b>	
Face	3 (15%)
Neck	2 (10%)
Trunk	3 (15%)
Extremities	10 (50%)
Acral	2 (10%)
<b>Skin type</b>	
I	0 (0%)
II	0 (0%)
III	15 (75%)
IV	5 (25%)
<b>Family history</b>	
Negative	18 (90%)
Positive	2 (10%)

UNDER PEER REVIEW

**Table (2):** The degree of clinical improvement in the studied patients (n= 20)

	<b>No.</b>	<b>%</b>
<b>Degree of clinical improvement</b>		
No	4	20.0
Mild	9	45.0
Moderate	5	25.0
Good	2	10.0
Excellent	<b>0</b>	<b>0.0</b>

**Table (3):** The degree of patient satisfaction in the studied patients (n= 20)

<b>Patient satisfaction</b>	<b>No.</b>	<b>%</b>
Not satisfied	9	45.0
Satisfied	8	40.0
Very satisfied	3	15.0



**Figure (1):** Dermapen and its disposable needle ((MY M microneedling, korea)).

UNDER PEER REVIEW



**Figure (2):** A 26-years-old male with vitiligo in extremities (A); Before treatment (B); Immediately after treatment session (C); 3 months after last session with good improvement.

UNDER PEER REVIEW



UNDER PEER REVIEW